Why the study?
Does FDG-PET or PET/CT accurately assess the response to neoadjuvant treatment in patients with osteosarcoma?
Does FDG-PET or PET/CT accurately assess the response to neoadjuvant treatment in patients with osteosarcoma?
FDG-PET and PET/CT are sensitive and reliable tools for assessing metabolic response to neoadjuvant treatment in osteosarcoma, despite potential false positives from inflammation.
Answers are grounded in this paper and cite their sources.
Supports FDG-PET/CT for neoadjuvant response monitoring in osteosarcoma; extends Level 1 evidence for metabolic imaging with inflammation caution.
Aim. The objective of this study is to systematically review the role of positron emission tomography (PET) and PET/computed tomography (PET/CT) with fluorine-18-fluorodeoxyglucose (FDG) in assessing the response to neoadjuvant treatment in patients with osteosarcoma (OS). Methods. A comprehensive literature search of published studies through March 2012 in PubMed/MEDLINE, Embase, and Scopus databases regarding whole-body FDG-PET and FDG-PET/CT in patients with OS was performed. Results. Twenty-two studies have investigated the role of FDG-PET and FDG-PET/CT in the evaluation of response to neoadjuvant treatment with either chemotherapy or radiation therapy in patients with OS. The main findings of these studies are presented. Conclusion. FDG-PET or PET/CT seems to be sensitive and reliable diagnostic tools in the assessment of metabolic response to treatment in patients with OS, after baseline PET evaluation has been performed in advance. However, false positive findings due to inflammation in sites of tumoral response should be considered.
No takes yet. Share an insight, caveat, or question.
Caldarella et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: